Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Michigan
With
GlaxoSmithKline
Age
30–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Type 2 diabetes
30-75 years of age
less than 1% fluctuation in HbA1c over 3 months
women must be on contraception
HbA1c 6-9%
willingness to sign approved consent form
You may not be if
Nursing mothers, pregnant women (excluded by a negative pregnancy test).
Subjects requiring insulin therapy (\>20 units/day) and can not be converted to sulfonylurea therapy without loss of diabetes control.
Patients with a history of drug or alcohol dependence in the last 5 years
Patients with pre-existing cardiovascular disease including coronary artery disease, heart attack, heart failure, abnormal heart rhythms, structural abnormalities and valve disease, peripheral vascular disease and uncontrolled high blood pressure.
Patients with a history of high cholesterol requiring therapy.
Patients with severe systemic disease other than diabetes which has as a recognized complication neuropathy
Patients currently taking drugs which act on the blood vessels (for example for hypertension)
Patients taking antidepressants, or other drugs or medications known to interfere with the uptake or metabolism of catecholamines (stress hormones)
Patients with poor renal function or have significant liver disease
Patients with a history of previous kidney, pancreas or cardiac transplantation.
Patients with a history of "severe hypoglycemia" which required the assistance of a third party or ketoacidosis requiring hospital admission within the last 3 months.
Patients with lung disease for example resulting from chronic obstructive airways disease.
Patients with abnormal thyroid function tests.
Patients having taken other systemic investigational drugs (especially for neuropathy) or initiating a new or experimental insulin delivery device within 3 months of starting the study.
Patients with a history of allergic reactions to multiple drugs or biological products.
Obese patients (BMI greater than 35).
Patients who refuse to sign the informed consent.
Clareo Health | Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes
